MA38318A1 - Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer - Google Patents

Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer

Info

Publication number
MA38318A1
MA38318A1 MA38318A MA38318A MA38318A1 MA 38318 A1 MA38318 A1 MA 38318A1 MA 38318 A MA38318 A MA 38318A MA 38318 A MA38318 A MA 38318A MA 38318 A1 MA38318 A1 MA 38318A1
Authority
MA
Morocco
Prior art keywords
ionizing radiation
inorganic nanoparticles
cancer
compositions
treatment
Prior art date
Application number
MA38318A
Other languages
English (en)
Inventor
Agnès Pottier
Laurent Levy
Elsa Borghi
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MA38318A1 publication Critical patent/MA38318A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1087—Ions; Protons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1089—Electrons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des nanoparticules inorganiques activables pouvant être utilisées dans le secteur de la santé, en particulier de la santé humaine, pour perturber, modifier ou détruire des cellules, tissus ou organes cibles cancéreux. Elle concerne plus particulièrement des nanoparticules pouvant générer un effet thérapeutique significativement efficace, lorsqu'elles sont concentrées à l'intérieur de la tumeur et exposées à des rayonnements ionisants. L'invention concerne également des compositions pharmaceutiques contenant un ensemble de nanoparticules telles que définies précédemment, ainsi que leurs utilisations.
MA38318A 2013-01-25 2014-01-24 Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer MA38318A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305087 2013-01-25
PCT/EP2014/051367 WO2014114732A1 (fr) 2013-01-25 2014-01-24 Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA38318A1 true MA38318A1 (fr) 2017-02-28

Family

ID=47710064

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38318A MA38318A1 (fr) 2013-01-25 2014-01-24 Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer

Country Status (23)

Country Link
US (4) US10098952B2 (fr)
EP (1) EP2948179B1 (fr)
JP (2) JP6619231B2 (fr)
KR (2) KR102225239B1 (fr)
CN (1) CN105120897B (fr)
AR (1) AR094577A1 (fr)
AU (1) AU2014209899B2 (fr)
BR (1) BR112015017490A2 (fr)
CA (2) CA2897362C (fr)
CY (1) CY1121838T1 (fr)
EA (1) EA034242B1 (fr)
HK (1) HK1216609A1 (fr)
IL (1) IL239767B (fr)
MA (1) MA38318A1 (fr)
MX (1) MX369664B (fr)
PL (1) PL2948179T3 (fr)
RS (1) RS59042B1 (fr)
SG (1) SG11201505277VA (fr)
SI (1) SI2948179T1 (fr)
TW (1) TW201442726A (fr)
UA (1) UA116007C2 (fr)
WO (1) WO2014114732A1 (fr)
ZA (1) ZA201505510B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857260C (fr) 2011-12-16 2019-10-15 Nanobiotix Nanoparticules comprenant des materiaux metalliques et d'oxydes d'hafnium, leur preparation et utilisations
KR102225239B1 (ko) 2013-01-25 2021-03-09 나노비오?笭? 암 치료용 이온화 방사선과 조합된 무기 나노입자 조성물
EP2886128A1 (fr) * 2013-12-20 2015-06-24 Nanobiotix Compositions pharmaceutiques comportant des nanoparticules, leur préparation et leur utilisation
TW201705977A (zh) 2015-05-28 2017-02-16 奈諾生技公司 作為治療疫苗之奈米顆粒
US11278723B2 (en) * 2016-12-21 2022-03-22 Nanobiotix S.A. Nanoparticles for use for treating a neuronal disorder
JP2020504732A (ja) * 2016-12-21 2020-02-13 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 脳活動の増強に使用するための、又はストレスの処置に使用するためのナノ粒子
EP3424533A1 (fr) * 2017-07-05 2019-01-09 Nh Theraguix Procédés de traitement de la dépendance
EP3654976A1 (fr) * 2017-07-21 2020-05-27 Varian Medical Systems, Inc. Procédés d'utilisation de rayonnement à débit de dose ultra élevé et d'agents thérapeutiques
JP2022540652A (ja) 2019-07-12 2022-09-16 オレゴン ヘルス アンド サイエンス ユニバーシティ 分裂期キナーゼ阻害剤と免疫チェックポイント阻害剤との同時送達のための治療用構築物
US20220249389A1 (en) * 2019-07-12 2022-08-11 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
WO2021011496A1 (fr) * 2019-07-12 2021-01-21 Oregon Health & Science University Constructions immunothérapeutiques et leurs procédés d'utilisation
WO2021215952A1 (fr) 2020-04-24 2021-10-28 Общество С Ограниченной Ответственностью "Индженик" Procédé de production de particules de bactériophages de la famille levivirus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006244A2 (fr) * 1998-07-30 2000-02-10 Hainfeld James F Particules metalliques de chargement dans des vesicules membranaires cellulaires et particule metallique utilisee pour l'imagerie et la therapie
BR0115127A (pt) * 2000-11-20 2004-02-17 Oncolytics Biotech Inc Método de fornecer um vìrus a um tumor sólido para reduzir crescimento do tumor
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
FR2884149B1 (fr) * 2005-04-12 2007-06-08 Henri Mehier Tube implantable destine a l'injection notamment de fluide caloporteur dans tout ou partie d'un tissu humain ou animal
EP2130553A1 (fr) * 2008-06-05 2009-12-09 Nanobiotix Nanoparticules inorganiques de haute densité pour détruire des cellules in-vivo
US8395131B2 (en) * 2009-06-20 2013-03-12 Xiaodong Wu Method for three dimensional (3D) lattice radiotherapy
EP2275137A1 (fr) * 2009-07-10 2011-01-19 Nanobiotix Nanoparticules métalliques, leur préparation et utilisations
EP2555800B1 (fr) 2010-04-05 2018-03-21 Nanospectra Biosciences, Inc. Amélioration d'une thérapie par rayonnement par nanoparticules ciblées à z élevé
CA2857260C (fr) * 2011-12-16 2019-10-15 Nanobiotix Nanoparticules comprenant des materiaux metalliques et d'oxydes d'hafnium, leur preparation et utilisations
KR102225239B1 (ko) 2013-01-25 2021-03-09 나노비오?笭? 암 치료용 이온화 방사선과 조합된 무기 나노입자 조성물

Also Published As

Publication number Publication date
WO2014114732A1 (fr) 2014-07-31
KR102225239B1 (ko) 2021-03-09
SG11201505277VA (en) 2015-08-28
RS59042B1 (sr) 2019-08-30
US20210283256A1 (en) 2021-09-16
MX2015009409A (es) 2016-03-16
AU2014209899B2 (en) 2018-05-24
CN105120897B (zh) 2017-12-05
JP2018168162A (ja) 2018-11-01
SI2948179T1 (sl) 2019-09-30
PL2948179T3 (pl) 2019-10-31
US11020480B2 (en) 2021-06-01
CN105120897A (zh) 2015-12-02
KR102385193B1 (ko) 2022-04-12
KR20150108923A (ko) 2015-09-30
US11819548B2 (en) 2023-11-21
US20150374818A1 (en) 2015-12-31
EP2948179A1 (fr) 2015-12-02
CA3179586A1 (fr) 2014-07-31
CY1121838T1 (el) 2020-07-31
IL239767B (en) 2018-10-31
TW201442726A (zh) 2014-11-16
US10098952B2 (en) 2018-10-16
JP2016505061A (ja) 2016-02-18
IL239767A0 (en) 2015-08-31
BR112015017490A2 (pt) 2017-07-11
ZA201505510B (en) 2016-12-21
JP6619231B2 (ja) 2019-12-11
UA116007C2 (uk) 2018-01-25
AU2014209899A1 (en) 2015-07-23
US20240100163A1 (en) 2024-03-28
EA034242B1 (ru) 2020-01-21
MX369664B (es) 2019-11-14
KR20210027536A (ko) 2021-03-10
AR094577A1 (es) 2015-08-12
EA201591378A1 (ru) 2016-04-29
US20190008962A1 (en) 2019-01-10
CA2897362A1 (fr) 2014-07-31
CA2897362C (fr) 2023-02-14
HK1216609A1 (zh) 2016-11-25
EP2948179B1 (fr) 2019-06-19

Similar Documents

Publication Publication Date Title
MA38318A1 (fr) Compositions de nanoparticules inorganiques combinées à des rayonnements ionisants pour le traitement du cancer
MA33516B1 (fr) Nanoparticules métalliques, leur préparation et leurs utilisations
NZ602635A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents
PE20191303A1 (es) Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
CO6670568A2 (es) Métodos de terapia combinada para tratar enfermedades profilerativas
IN2012DN02018A (fr)
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
NI201200179A (es) Métodos de tratamiento contra el cáncer pancreático
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
BRPI0507039A8 (pt) composição, métodos de tratar um paciente com câncer, e de inibir a angiogênese em um tumor, e, kit
EP4140487A8 (fr) Polythérapie anticancéreuse
NZ603952A (en) Phosphaplatins and their use for treatment of cancers
WO2019043176A3 (fr) Inhibiteur de l'histone-désacétylase en association avec un agent antimétabolite pour la cancérothérapie
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
MA49444A (fr) Combinaison d'un inhibiteur de mcl-1 et d'un standard de traitement de soin pour cancers hématologiques, utilisations et compositions pharmaceutiques associées
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.
NZ750194A (en) Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
EA202190291A1 (ru) Комбинированная терапия для лечения рака